|
1
|
Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y,
Xu JS, Huang SM, Wang LN, Huang W, et al: Modified glomerular
filtration rate estimating equation for chinese patients with
chronic kidney disease. J Am Soc Nephrol. 17:2937–2944. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Levey AS, de Jong PE, Coresh J, El Nahas
M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL and Eckardt
KU: The definition, classification, and prognosis of chronic kidney
disease: A KDIGO controversies conference report. Kidney Int.
80:17–28. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coresh J, Selvin E, Stevens LA, Manzi J,
Kusek JW, Eggers P, van Lente F and Levey AS: Prevalence of chronic
kidney disease in the United States. JAMA. 298:2038–2047. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fogo AB: Mechanisms of progression of
chronic kidney disease. Pediatr Nephrol. 22:2011–2022. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chevalier RL, Forbes MS and Thornhill BA:
Ureteral obstruction as a model of renal interstitial fibrosis and
obstructive nephropathy. Kidney Int. 75:1145–1152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Y and Harris DC: Macrophages in renal
disease. J Am Soc Nephrol. 22:21–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murray PJ and Wynn TA: Protective and
pathogenic functions of macrophage subsets. Nat Rev Immunol.
11:723–737. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Owen MR, Stamper IJ, Muthana M, Richardson
GW, Dobson J, Lewis CE and Byrne HM: Mathematical modeling predicts
synergistic antitumor effects of combining a macrophage-based,
hypoxia-targeted gene therapy with chemotherapy. Cancer Res.
71:2826–2837. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spitler LE, Grossbard ML, Ernstoff MS,
Silver G, Jacobs M, Hayes FA and Soong SJ: Adjuvant therapy of
stage III and IV malignant melanoma using granulocyte-macrophage
colony-stimulating factor. J Clin Oncol. 18:1614–1621. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahmadian M, Suh JM, Hah N, Liddle C,
Atkins AR, Downes M and Evans RM: PPARγ signaling and metabolism:
The good, the bad and the future. Nat Med. 19:557–566. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murphy GJ and Holder JC: PPAR-γ agonists:
Therapeutic role in diabetes, inflammation and cancer. Trends
Pharmacol Sci. 21:469–474. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang J, Zhang Y, Xiao F, Liu Y, Wang J,
Gao H, Rong S, Yao Y, Li J and Xu G: The peroxisome
proliferator-activated receptor γ agonist pioglitazone prevents
NF-κB activation in cisplatin nephrotoxicity through the reduction
of p65 acetylation via the AMPK-SIRT1/p300 pathway. Biochem
Pharmacol. 101:100–111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hontecillas R, Horne WT, Climent M, Guri
AJ, Evans C, Zhang Y, Sobral BW and Bassaganya-Riera J:
Immunoregulatory mechanisms of macrophage PPAR-γ in mice with
experimental inflammatory bowel disease. Mucosal Immunol.
4:304–313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Y, Wang J, Zhou QD, Zhang CH, Li Q,
Huang S, Zhan J, Wang K, Liu YY and Xu G: Peroxisome
proliferator-activated receptor-γ agonist pioglitazone fails to
attenuate renal fibrosis caused by unilateral ureteral obstruction
in mice. J Huazhong Univ Sci Technol Med Sci. 36:41–47. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, Wang K, Liang X, Li Y, Zhang Y,
Zhang C, Wei H, Luo R, Ge S and Xu G: Complement C3 produced by
macrophages promotes renal fibrosis via IL-17A secretion. Front
Immunol. 9:23852018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ying W, Cheruku PS, Bazer FW, Safe SH and
Zhou B: Investigation of macrophage polarization using bone marrow
derived macrophages. J Vis Exp. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Duffield JS: Macrophages and immunologic
inflammation of the kidney. Semin Nephrol. 30:234–254. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nikolic-Paterson DJ, Wang S and Lan HY:
Macrophages promote renal fibrosis through direct and indirect
mechanisms. Kidney Int Suppl (2011). 4:34–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang YY, Jiang H, Pan J, Huang XR, Wang
YC, Huang HF, To KF, Nikolic-Paterson DJ, Lan HY and Chen JH:
Macrophage-to-myofibroblast transition contributes to interstitial
fibrosis in chronic renal allograft injury. J Am Soc Nephrol.
28:2053–2067. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tuccori M, Filion KB, Yin H, Yu OH, Platt
RW and Azoulay L: Pioglitazone use and risk of bladder cancer:
Population based cohort study. BMJ. 352:i15412016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li H, Sorenson AL, Poczobutt J, Amin J,
Joyal T, Sullivan T, Crossno JT Jr, Weiser-Evans MC and Nemenoff
RA: Activation of PPARγ in myeloid cells promotes lung cancer
progression and metastasis. PLoS One. 6:e281332011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu Z, Ding J, Ma Z, Iwashina T and
Tredget EE: Alternatively activated macrophages derived from THP-1
cells promote the fibrogenic activities of human dermal
fibroblasts. Wound Repair Regen. 25:377–388. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tammela T and Alitalo K:
Lymphangiogenesis: Molecular mechanisms and future promise. Cell.
140:460–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su JL, Yen CJ, Chen PS, Chuang SE, Hong
CC, Kuo IH, Chen HY, Hung MC and Kuo ML: The role of the
VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 96:541–545.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
D'Alessio S, Correale C, Tacconi C,
Gandelli A, Pietrogrande G, Vetrano S, Genua M, Arena V, Spinelli
A, Peyrin-Biroulet L, et al: VEGF-C-dependent stimulation of
lymphatic function ameliorates experimental inflammatory bowel
disease. J Clin Invest. 124:3863–3878. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Beghdadi W, Madjene LC, Claver J, Pejler
G, Beaudoin L, Lehuen A, Daugas E and Blank U: Mast cell chymase
protects against renal fibrosis in murine unilateral ureteral
obstruction. Kidney Int. 84:317–326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sugawara A, Uruno A, Kudo M, Matsuda K,
Yang CW and Ito S: Effects of PPARγ on hypertension,
atherosclerosis, and chronic kidney disease. Endocr J. 57:847–852.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rosen ED and Spiegelman BM: PPARgamma: A
nuclear regulator of metabolism, differentiation, and cell growth.
J Biol Chem. 276:37731–37734. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fogo AB: PPARγ and chronic kidney disease.
Pediatr Nephrol. 26:347–351. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang HC, Deleuze S, Zuo Y, Potthoff SA, Ma
LJ and Fogo AB: The PPARgamma agonist pioglitazone ameliorates
aging-related progressive renal injury. J Am Soc Nephrol.
20:2380–2388. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Singh AP, Singh N and Bedi PM:
Pioglitazone ameliorates renal ischemia reperfusion injury through
NMDA receptor antagonism in rats. Mol Cell Biochem. 417:111–118.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Blazer-Yost BL, Haydon J, Eggleston-Gulyas
T, Chen JH, Wang X, Gattone V and Torres VE: Pioglitazone
attenuates cystic burden in the PCK rodent model of polycystic
kidney disease. PPAR Res. 2010:2743762010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ochodnicky P, Mesarosova L, Cernecka H,
Klimas J, Krenek P, Goris M, van Dokkum RP, Henning RH and
Kyselovic J: Pioglitazone, a PPARγ agonist, provides comparable
protection to angiotensin converting enzyme inhibitor ramipril
against adriamycin nephropathy in rat. Eur J Pharmacol. 730:51–60.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Higashi K, Oda T, Kushiyama T, Hyodo T,
Yamada M, Suzuki S, Sakurai Y, Miura S and Kumagai H: Additive
antifibrotic effects of pioglitazone and candesartan on
experimental renal fibrosis in mice. Nephrology (Carlton).
15:327–335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Han JY, Kim YJ, Kim L, Choi SJ, Park IS,
Kim JM, Chu YC and Cha DR: PPARgamma agonist and angiotensin II
receptor antagonist ameliorate renal tubulointerstitial fibrosis. J
Korean Med Sci. 25:35–41. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sun L, Yuan Q, Xu T, Yao L, Feng J, Ma J,
Wang L, Lu C and Wang D: Pioglitazone improves mitochondrial
function in the remnant kidney and protects against renal fibrosis
in 5/6 nephrectomized rats. Front Pharmacol. 8:5452017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nishida M and Hamaoka K: Macrophage
phenotype and renal fibrosis in obstructive nephropathy. Nephron
Exp Nephrol. 110:e31–36. 2008. View Article : Google Scholar : PubMed/NCBI
|
